miR-29b inhibits the progression of esophageal squamous cell carcinoma by targeting MMP-2

Neoplasma

Volumn 62, Issue 3, 2015, Pages 384-390

  Qi, Y ^a   Li, X ^a   Zhao, S ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Invasion; MiR 29b; MMP 2

Indexed keywords

GELATINASE A; MICRORNA 29B;

ADULT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL INVASION; CELL INVASION ASSAY; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84969745131     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_046     Document Type: Article

References (31)

1. LIN Y, TOTSUKA Y, HE Y, KIKUCHI S, QIAO Y, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol 2013; 23: 233-42. http: //dx. doi. org/10. 2188/jea. TE20120162
2. WHEELER JB, REED CE. Epidemiology of esophageal cancer. Surg Clin North Am 2012; 92: 1077-87. http: //dx. doi. org/10. 1016/j. SUC. 2012. 07. 008
3. TOH Y, OKI E, OHGAKI K, SAKAMOTO Y, ITO S, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol 2010; 15: 135-44. http: //dx. doi. org/10. 1007/s10147-010-0057-6
4. STONER CD, WANG LS. Chemoprevention of esophageal squamous cell carcinoma with berries. Top Curr Chem 2013; 329: 1-20.
5. THALLINGER CM, KIESEWETTER B, RADERER M, HEJNA M. Pre-and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res 2012; 32: 4609-27.
6. STONER GD, WANG LS, CHEN T. Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol 2007; 224: 337-49. http: //dx. doi. Org/10. 1016/j. taap. 2007. 01. 030
7. YOSHINO H, SEKI N, ITESAKO T, CHIYOMARU T, NA-KAGAWA M, et al. Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol 2013; 10: 396-404. http: //dx. doi. org/10. 1038/nrurol. 2013. 113
8. FARAZI TA, HOELL JI, MOROZOV P, TUSCHL T. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1-20. http: //dx. doi. org/10. 1007/978-94-007-5590-l 1
9. BAER C, CLAUS R, PLASS C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 2013; 73: 473-7. http: //dx. doi. org/10. 1158/0008-5472. CAN-12-3731
10. MAYNE GC, HUSSEY DJ, WATSON DI. MicroRNAs and esophageal cancer-implications forpathogenesis and therapy. Curr Pharm Des 2013; 19: 1211-26.
11. NANA-SINKAM SP, CROCE CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104. http: //dx. doi. org/10. 1038/clpt. 2012. 192
12. QIANG W, LIU Z, SERNA VA, DRUSCHITZ SA, LIU Y, et al. Down-regulation of miR-29b is essential for pathogenesis of uterine leiomyoma. Endocrinology 2014; 155: 663-9. http: // dx. doi. org/10. 1210/en. 2013-1763
13. HIROKI E, AKAHIRA J, SUZUKI F, NAGASE S, ITO K, et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2010; 101: 241-9 http: // dx. doi. org/10. 1111/j. l349-7006. 2009. 01385. x
14. RU P, STEELE R, NEWHALL P, PHILLIPS NJ, TOTH K, et al. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 2012; 11: 1166-73. http: //dx. doi. org/10. 1158/1535-7163. MCT-12-0100
15. DAI F, ZHANG Y, CHEN Y. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol 2014; 45: 1285-93. http: //dx. doi. org/10. 1016/j. humpath. 2014. 02. 008
16. ROY R, YANG J, MOSES MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-5297. http: //dx. doi. org/10. 1200/JC0. 2009. 23. 5556
17. GROBLEWSKA M, SIEWKO M, MROCZKO B, SZ-MITKOWSKI M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol 2012; 50: 12-9. http: //dx. doi. org/ 10. 5603/FHC. 2012. 0002
18. PLANK M, MALTBY S, MATTES J, FOSTER PS. Targeting translational control as a novel way to treat inflammatory disease: the emerging role of microRNAs. Clin Exp Allergy 2013; 43: 981-99. http: //dx. doi. org/10. 1111/cea. 12135
19. LE QUESNE J, CALDAS C. Micro-RNAs and breast cancer. Mol Oncol 2010; 4: 230-41. http: //dx. doi. Org/10. 1016/j. molonc. 2010. 04. 009
20. LI P, GUO W, DU L, ZHAO J, WANG Y, et al. microRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells. Clin Sci (Lond) 2013; 124: 27-40. http: //dx. doi. org/10. 1042/CS20120121
21. WU DW, HSU NY, WANG YC, LEE MC, CHENG YW, et al. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene 2014 Jun 9; 0. doi: 10. 1038/onc. 2014. 152. [Epub ahead of print] http: //dx. doi. org/10. 1038/onc. 2014. 152
22. KRIEGEL AJ, LIU Y, FANG Y, DING X, LIANG M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44: 237-44. http: //dx. doi. org/10. 1152/phvsiolgenomics. 00141. 2011
23. SCHMITT MJ, MARGUE C, BEHRMANN I, KREIS S. MiRNA-29: a micro RNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med 2013; 13: 572-85. http: //dx. doi. org/10. 2174/15665240113130400Q9
24. CHEN KC, WANG YS, HU CY, CHANG WC, LIAO YC, et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 2011; 25: 1718-28. http: // dx. doi. org/10. 1096/fj. 10-174904
25. STEELE R, MOTT JL, RAY RB. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloprotein-ase-2 in prostate cancer cells. Genes Cancer. 2010; 1: 381-387. http: //dx. doi. org/10. 1177/1947601910371978
26. OKAMOTO K, MIYOSHI K, MURAWAKI Y. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One 2013; 8: e77623. http: //dx. doi. org/10. 1371/journal. pone. 0077623
27. KLEINER DE, STETLER-STEVENSON WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43 Suppl: S42-51 http: //dx. doi. org/10. 1007/ S002800051097
28. YOSHIZAKI T, SATO H, FURUKAWA M. Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication. Oncol Rep 2002; 9: 607-11.
29. CHIEN MH, LIN CW, CHENG CW, WEN YC, YANG SF. Matrix metalloproteinase-2 as a target for head and neck cancer therapy. Expert Opin Ther Targets 2013; 17: 203-16. http: //dx. doi. org/10. 1517/14728222. 2013. 740012
30. CHOU J, LINJ H, BRENOT A, KIM JW, PROVOT S, et al. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013; 15: 201-13. http: //dx. doi. org/10. 1038/ ncb2672
31. POUDYAL D, CUI X, LE PM, HOFSETH AB, WINDUST A, et al. A key role of micro RNA-29b for the suppression of colon cancer cell migration by American ginseng. PLoS One 2013; 8: e75034. http: //dx. doi. org/10. 1371/journal. pone. 0075034